| | By Kevin Dunleavy Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. In 2024, the FDA gave a thumbs-up to more than xx new treatments, which was down from 60-plus new drugs in 2023. |
|
|
|
By Fraiser Kansteiner The FDA approved Novo Nordisk's tissue factor pathway inhibitor (TFPI) antagonist concizumab as a once-a-day treatment to prevent or curb the frequency of bleeding episodes in patients ages 12 and older who have hemophilia A or B with inhibitors. The green light follows a rejection in 2023 and a trial pause over safety concerns several years before that. |
By James Waldron After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it’s found a sustainable path forward via a merger into privately owned immunology company Inmagene Biopharmaceuticals. |
By Fraiser Kansteiner As the life sciences industry prepares for a new administration, cutting edge technology and more, there are plenty of challenges in store for 2025—and much to be optimistic about, too. That’s according to the Deloitte U.S. Center for Health Solutions, which found in a recent survey of 150 C-suite executives across the global life sciences sphere that 75% of respondents are optimistic about the year ahead. |
By Darren Incorvaia Rising costs and a boom in obesity trials and AI are some of the predicted trends for the clinical trial industry in 2025. |
By Eric Sagonowsky For many readers, the topics featured in this year’s roundup of top stories won’t come as much of a surprise. Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center stage in 2024. |
By Gabrielle Masson For the end of this year, Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting. And readers have made it easy for us—it’s clear what kind of story drew the most interest. |
By Conor Hale A look back at our top stories of 2024 sees them fall into two major themes: promise, and a realignment of expectations. |
By Ben Adams It’s been a year of big stories about Big Pharmas in the healthcare marketing world. All our top 10 pieces, as read by you in 2024, relate to the biggest players in the industry and the biggest issues of the year, namely: AI, celebrity endorsements, marketing snafus and anti-obesity meds. |
By Fraiser Kansteiner While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been nothing short of a staggering financial success, the rollouts of the new class of cardiometabolic medicines have been consistently hamstrung by manufacturing and supply constraints. That said, "positive signals" are emerging around the future of GLP-1 supply, analysts at ZS opined. |
By Nick Paul Taylor A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss targeted by executives, prompting investors to wipe 19% off the value of the Danish drugmaker. |
By Joseph Keenan Viatris disclosed that its manufacturing facility in Indore, India, was issued a warning letter from the FDA, which banned 11 products that are produced at the site from being imported into the U.S. for distribution. |
By Darren Incorvaia An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in mice, the biotech announced Dec. 23. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees. |
|
|---|
|
|
Whitepaper There’s so much that goes into making sure your therapy maximizes impact every step of the way. Sponsored by: Accredo By Evernorth |
Research Read this case study to discover how programmatic EHR advertising can transform your omnichannel marketing strategy. Sponsored by: Veradigm |
| |
|
